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Abstract
 
Natural killer (NK) cells are critical in the immune response to tumor cells, virally infected
cells, and bone marrow allografts. 2B4 (CD244) is expressed on all NK cells and the ligand for
2B4, CD48, is expressed on hematopoietic cells. Cross-linking 2B4 on NK cells with anti-2B4
monoclonal antibody leads to NK cell activation in vitro. Therefore, 2B4 is considered to be
an activating receptor. Surprisingly, we have found, using antibody-blocking and 2B4-deficient
NK cells, that NK lysis of CD48
 
  
 
tumor and allogeneic targets is inhibited by 2B4 ligation.
Interferon 
 
  
 
production by NK cells is also inhibited. Using a peritoneal tumor clearance assay,
it was found that 2B4
 
 
 
/
 
  
 
mice have increased clearance of CD48
 
  
 
tumor cells in vivo. Retro-
viral transduction of 2B4 was sufficient to restore inhibition in 2B4
 
 
 
/
 
  
 
primary NK cells. It was
found that although mature NK cells express SH2D1A, in vitro–derived NK cells do not.
However, both populations are inhibited by 2B4 ligation. This indicates that 2B4 inhibitory
signaling occurs regardless of the presence of SH2D1A. These findings reveal a novel role for
2B4 as a non–major histocompatibility complex binding negative regulator of NK cells.
Key words: CD48 • CD150 • tumor • IFN-
 
  
 
• innate immunity
 
Introduction
 
NK cells are innate lymphocytes named for their ability to
lyse tumor cells. The functions of NK cells also include re-
sponding to viral infection, rejecting allogeneic bone marrow,
and promoting type 1 helper T cell responses (1, 2). Acti-
vating and inhibiting surface receptors expressed on par-
tially overlapping subsets of NK cells provide the specificity
for NK cell responses. Positive signals lead to activation of
cytokine production and cytotoxicity, but these signals can
be negated by simultaneous engagement of inhibitory re-
ceptors. Murine lectin-like Ly49 receptors and human
killer cell Ig-like receptors are two families that recognize
polymorphic epitopes of MHC class I molecules (3). A third
family, the CD94/NKG2 lectin-like heterodimer family, is
conserved in mice and humans and recognizes nonclassical
murine MHC class I Qa-1
 
b 
 
or human HLA-E (4). The inhib-
itory members of these families, which are essential for pro-
tecting normal cells from NK-mediated lysis, contain intra-
cellular immunoreceptor tyrosine-based inhibition motifs
(ITIMs; I/VxYxxL/V). Activating receptors of these families
lack an ITIM and are instead associated with immunoreceptor
tyrosine-based activation motif (D/ExxYxxL/Ix[6–8]YxxL/
I)–containing transmembrane adaptor molecules (5).
2B4 is an unusual NK receptor in that it is not regulated
by MHC molecules, nor does it contain ITIM or immu-
noreceptor tyrosine-based activation motifs. It is a member
of the CD150 (signaling lymphocyte activation molecule)
subfamily of the CD2 family of receptors. The members of
this subfamily are distinguished by the presence of at least
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two cytoplasmic immunoreceptor tyrosine-based switch
motifs (ITSMs; TxYxxV/I) and include 2B4, CD84,
CD229, NTB-A, and CS1 (6). Murine 2B4 has two iso-
forms derived from alternative splicing. The short form has
one ITSM, and the long form has four (7, 8). Human 2B4
is only found as the long form (9). 2B4 is expressed by all
NK cells, 
 
   
 
T cells, basophils, monocytes, and a subset of
CD8
 
  
 
   
 
T cells (10–13). The ligand for 2B4, CD48, is a
GPI-linked CD2 family member (14). CD48 is a low affin-
ity ligand for CD2 and a high affinity ligand for 2B4 and is
expressed on hematopoietic cells (14–16).
ITSMs bind SH2 domain–containing proteins including
SH2D1A (signaling lymphocyte activation molecule–associ-
ated protein) and a similar protein, EWS-activated transcript
2 (EAT-2; 17, 18). Mutations in SH2D1A are found in pa-
tients with X-linked lymphoproliferative disorder (XLP), a
progressive combined variable immunodeficiency often ag-
gravated by EBV infection (17, 19–22). It is possible that al-
tered signaling by ITSM-containing proteins, including
2B4, may contribute to the pathogenesis of XLP. One hy-
pothesis is that in the absence of functional SH2D1A, 2B4 is
unable to initiate an activating signal and instead recruits
phosphatases, thus becoming inhibitory (23–29).
Murine 2B4 was originally identified as an activating re-
ceptor because treatment of NK cells with anti-2B4 mAb
lead to increased IFN-
 
  
 
production and killing of tumor
cell lines in vitro (10). Human 2B4 was found to activate
NK cells in a redirected lysis assay using FcR
 
  
 
target cells
treated with anti-2B4 to cross-link 2B4 present on the ef-
fector cells (11). To elucidate the role of 2B4 in the regula-
tion of murine NK cells in more physiological experi-
ments, we have used 2B4
 
 
 
/
 
  
 
mice and ligand positive or
negative targets to investigate 2B4 function. Our data indi-
cate that 2B4 acts as a non-MHC binding inhibitory recep-
tor both in vitro and in vivo.
 
Materials and Methods
 
Mice.
 
C57BL/6 (B6, WT) and BALB/c mice were purchased
from NCI-Frederick. SCID mice were obtained from Jackson
ImmunoResearch Laboratories. 2B4
 
 
 
/
 
  
 
mice are described else-
where (unpublished data). In brief, 2B4
 
 
 
/
 
  
 
mice were generated
by insertion of a pPNT construct encoding bacterial aminoglyco-
side phosphotransferase under a phosphoglycerate kinase promoter
(PGK-neo
 
r
 
) flanked by PCR-cloned 2B4 DNA. The vector re-
placed the extracellular region, exon 2 and part of exon 3, with
the PGK-neo
 
r 
 
gene. Embryonic stem cells derived from C57BL/6
mice were used. 2B4-deficient mice expressed no 2B4 as deter-
mined by flow cytometry. All mice were used at 6–12 wk of age.
B6 controls for 2B4
 
 
 
/
 
  
 
mice were age matched.
 
Cell Lines.
 
RMA-S (H-2
 
b 
 
low, thymoma cells) CD48
 
 
 
,
RMA-S CD48
 
 
 
, and P815 (H-2
 
d
 
, mastocytoma cells) were cul-
tured in RPMI 1640 with 
 
l
 
-glutamine, supplemented with 10%
FBS, 100 U/ml penicillin, 100 U/ml streptomycin, 1 mM sodium
pyruvate, 0.1 mM nonessential amino acids, and 50 
 
 
 
M 2-ME
(complete RPMI) at 37
 
 
 
C and 5% CO
 
2
 
. The CD48
 
  
 
RMA-S cell
line arose spontaneously from the CD48
 
  
 
RMA-S during culture.
To generate CD48
 
  
 
P815 cells, CD48 cDNA was cloned into the
pcDNA3.1 expression vector that was then stably transfected into
CD48
 
  
 
P815 cells. CD48
 
  
 
P815 cells stably transfected with an
empty vector were used as the control CD48
 
  
 
cell line.
 
Antibodies and Flow Cytometry.
 
Anti-CD16/32 (anti-FcR
 
 
 
III,
2.4G2, anti-FcR) was produced from a hybridoma. Purified and
fluorescently labeled mAbs purchased from BD Biosciences are:
anti-FcR, anti-2B4 (2B4), anti-CD48 (HM48-1), anti-CD2
(RM2-5), anti-DX5 (DX5), hamster IgG1
 
 
 
, mouse IgG2b
 
 
 
, and
rat IgG1
 
 
 
. Anti–IFN-
 
  
 
(XMG1.2), anti-NK1.1 (PK136), and
anti-CD3 (145-2C11) were purchased from eBioscience. For im-
munofluorescence analysis, cells were suspended in PBS with 2%
FBS after blocking with anti-FcR supernatant. Cells were incu-
bated in the indicated antibodies for 30 min. Analysis was per-
formed on a FACSCalibur™ flow cytometer with CELLQuest™
software (BD Biosciences). Detection of intracellular IFN-
 
  
 
was
performed by incubation of 10
 
5 
 
lymphokine-activated killer
(LAK) cells with 10
 
5 
 
RMA-S cells for 6 h in the presence of
GolgiStop (BD Biosciences). Cells were washed, surface stained
as described above, and then permeabilized with Cytofix/Cyto-
perm Kit (BD Biosciences) according to the manufacturer’s direc-
tions. Cells were then stained with anti–IFN-
 
 
 
–PE or isotype
control.
 
Ex Vivo–derived Cell Preparations.
 
NK cells were enriched by
passage of splenic cell suspensions through a nylon wool column
for negative depletion of adherent cells followed by magnetic de-
pletion of CD3
 
  
 
cells using anti-CD3 biotin and magnetic mi-
crobeads coated with streptavidin (Miltenyi Biotec). Cells bound
to microbeads were depleted using a MACS separation column
according to the manufacturer’s instructions (Miltenyi Biotec).
LAK cells were generated by culturing the remaining cells in
complete RPMI with 1,000 U/ml human rIL-2 (National Insti-
tutes of Health [NIH]). On day 3 after the onset of culture, half
the media was replaced with fresh media containing IL-2. LAK
cells were used on days 6–10 for experiments and were 
 
 
 
95%
NK1.1
 
  
 
CD3
 
 
 
. In vitro–derived NK cells were obtained from
bone marrow cell suspensions as previously described (30). Bone
marrow cells were released from femurs, tibias, sternum, and pel-
vic bones by mortar and pestle. Lineage
 
  
 
cells were depleted
using biotin-conjugated anti-CD2, anti-B220 (RA3-6B2), anti–
Gr-1 (RB6-8C5), anti-CD11b (M1/70), anti-NK1.1, and anti-
Ter119 (Ly-76; BD Biosciences) followed by streptavidin micro-
beads and MACS columns. c-kit
 
  
 
cells were positively selected
by anti–ckit-FITC (BD Biosciences) followed by anti-FITC mi-
crobeads and MACS columns. Cells were cultured in 0.5 ng/ml
murine IL-7, 50 ng/ml murine stem cell factor, and 20 ng/ml
human Flt3L (Biosource International) for 5 d followed by 6 d in
1,000 U/ml IL-2 and complete RPMI.
 
In Vitro Cytotoxicity Assay.
 
10
 
6 
 
target cells were labeled with
100 
 
 
 
Ci of sodium chromate (
 
51
 
Cr) for 1 h at 37
 
 
 
C. Target cells
were washed and 2,000/well were plated in 96-well plates. Effec-
tor cells at indicated E/T ratios were added. After 4 h of incuba-
tion, supernatants were collected and percent-specific lysis was
calculated using standard methods. Cells pretreated with blocking
antibodies were incubated at 5 
 
 
 
g/ml with the indicated anti-
body for 15 min on ice after similar blocking with anti-FcR
where indicated. Con A–stimulated targets were generated by
culturing either whole splenocytes or splenocytes depleted of ny-
lon wool adherent cells for 24 or 48 h with 3 
 
 
 
g/ml Con A
(Sigma-Aldrich). Con A targets were whole splenocytes stimu-
lated for 48 h unless otherwise stated. Data are the mean 
 
  
 
stan-
dard deviation from triplicates from one representative experi-
ment of at least three independent experiments.
 
RT-PCR.
 
Total RNA was isolated from LAK cells, in vitro–
derived NK cells, and thymocytes using RNeasy Mini Kit 
Lee et al.
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(QIAGEN) and was reverse transcribed. The primers used for am-
plification of SH2D1A cDNA (394 bp) were 5
 
  
 
CTA GGC ATG
GAT GCA GTG ACT GTG and 3
 
  
 
ACT CTT CTT CAT GGT
GCA TTC AGG. The primers used for amplification of EAT-2
cDNA (313 bp) were 5
 
  
 
GAC CAA GCG AGA GTG TGA and
3
 
  
 
CTC CAT TCT TCT CCC TCT TTG GCA. Amplification
was performed for 35 cycles: 30 s at 94
 
 
 
C, 60 s at 58
 
 
 
C, and 2 min
at 72
 
 
 
C. PCR products were resolved on a 1% agarose gel.
 
Retroviral Transduction.
 
Retroviral transduction was per-
formed as previously described (31). In brief, murine 2B4 short or
2B4 long cDNA was inserted in the SAMEN CMV/SR
 
  
 
vector
under a hybrid promoter consisting of a CMV enhancer and pro-
moter fused to Moloney murine leukemia virus 5
 
  
 
LTR (32),
which allows maximum expression of transduced genes. Infectious
retroviral supernatants were generated by transient transfection
with 10 
 
 
 
g of either empty vector or vector containing 2B4 long
or 2B4 short cDNA into 5 
 
  
 
10
 
6 
 
Plat-E ecotropic packaging cells
(33) plated on 10-cm dishes 16 h before the transfection. Trans-
fection was performed using a standard Hepes-buffered calcium
phosphate coprecipitation method. The next day, the media was
removed and replaced with 3 ml fresh media. After an additional
48 h, the supernatant was collected, centrifuged at 3,000 rpm for
10 min, and filtered with a 0.45-
 
 
 
m filter to remove cell debris,
and aliquots were stored at 
 
 
 
80
 
 
 
C. NK cells cultured in IL-2 for
5 d were plated at a density of 1.5 
 
  
 
10
 
6 
 
cells/well in 24-well
plates and were transduced by adding 1 ml retroviral supernatants
containing 2B4 short, 2B4 long, or empty vector in the presence
of 10 
 
 
 
g/ml polybrene (Sigma-Aldrich). Plates were spun at 1,500
rpm at 4
 
 
 
C for 1.5 h and then incubated at 37
 
 
 
C for 18 h. This
process was repeated and NK cells were used on the next day.
CD48
 
  
 
RMA-S cells were transduced with either empty vector
or SAMEN vector containing murine CD48 cDNA according to
the same method, and selected with neomycin.
 
In Vivo Cytotoxicity Assay.
 
RMA-S cells suspended in PBS
were labeled with 5 
 
 
 
M carboxyl fluorescein succinimidyl ester
(CFSE; Molecular Probes) at 37
 
 
 
C for 10 min and the reaction
was quenched with an equal volume of FBS. Cells were washed
in PBS, and 5 
 
  
 
10
 
6 
 
CD48
 
  
 
or 10 
 
  
 
10
 
6 
 
CD48
 
  
 
RMA-S cells
were injected i.p. in 500 
 
 
 
l PBS. Titration of tumor cells was
performed and cell numbers injected reflect the number necessary
to detect residual tumor cells after 3 d (unpublished data). After
3 d, the mice were killed and peritoneal cells were recovered.
Tumor cells were distinguished by forward versus side scatter and
CFSE labeling. Mice that failed to engraft were excluded from
analysis. For NK depletion controls, mice were injected i.p. with
100 
 
 
 
g anti-NK1.1 2 d before tumor injection and again on the
day of the injection. Depletion of NK cells was complete as no
DX5
 
  
 
CD3
 
  
 
cells remained in the peritoneum on day 3 as deter-
mined by flow cytometry (unpublished data).
 
Results
 
2B4 Inhibits NK Cell Lysis of CD48
 
  
 
Tumor Cells In Vi-
tro.
 
To investigate the role of 2B4 signaling in the regula-
tion of NK cell cytotoxicity, we identified cell lines that
were either CD48
 
  
 
or CD48
 
  
 
(Fig. 1 A). CD48
 
  
 
RMA-S
(H-2
 
b 
 
low, FcR
 
 
 
) tumor cells, or a variant that is CD48
 
 
 
,
were then tested as NK targets in killing assays. Purified
WT NK cells expanded in IL-2 (LAK cells) lyse CD48
 
 
 
RMA-S but surprisingly, lysed CD48
 
  
 
targets much less ef-
ficiently (Fig. 1 B). To determine if this inhibition was due
to CD48 ligation of 2B4, CD48  RMA-S cells were pre-
treated with anti-CD48 to block 2B4–CD48 interaction.
Blocking 2B4 ligation with anti-CD48 antibody restored
NK lysis of CD48  RMA-S (Fig. 1 D). Although the NK
cells were pretreated with anti-FcR antibody to block FcR
binding of anti-CD48 and subsequent antibody-dependent
cellular cytotoxicity (ADCC), it could not be ruled out
that the lysis of CD48  targets was contributed to by
ADCC. To exclude this possibility, NK cells were pre-
treated with anti-2B4 or isotype control antibody. Anti-
2B4 treatment of NK cells also increased cytotoxicity
against CD48 , but not CD48  RMA-S (Fig. 1 C). This
confirmed that 2B4 and CD48 interaction was inhibitory.
To test if expression of CD48 could protect CD48  cells
from NK lysis, CD48  RMA-S cells were transduced with
Figure 1. Ligation of 2B4 by CD48 expressed on tumor cells inhibits
NK cytotoxicity. (A) CD48  and CD48  RMA-S cells were stained with
anti-CD48 (open histogram) or isotype control (shaded histogram). (B) WT
LAK cells were tested in a 4-h chromium release assay against CD48  or
CD48  RMA-S cells at the indicated E/T ratios. (C) WT LAK cells were
pretreated with anti-FcR and either anti-2B4 or isotype control and
tested against CD48  or CD48  RMA-S. (D) WT LAK cells were tested
against CD48  RMA-S. NK cells were pretreated with anti-FcR and targets
were pretreated with or without anti-CD48. (E) CD48  RMA-S cells
were transduced with CD48 or control empty vector and tested as targets
of WT NK cells. (F) WT LAK cells were pretreated with anti-2B4 or iso-
type control antibody and tested for killing of CD48  P815 or P815
transfected with CD48. (G) WT and 2B4 /  LAK cells were tested
against CD48  and CD48  RMA-S targets.2B4 Inhibition of NK Cells 1248
CD48. Although vector-transduced CD48  RMA-S re-
mained sensitive to NK cells, CD48 expression shielded
RMA-S from lysis (Fig. 1 E). Another tumor cell line,
P815, was also tested with similar results. CD48  P815 cells
were killed by NK cells, but the lysis of CD48  P815 cells
was inhibited by transfection with CD48 (Fig. 1 F). This
inhibition was specific to 2B4–CD48 interaction, as it was
completely relieved by anti-2B4 blocking (Fig. 1 F). Thus,
CD48 engagement of 2B4 inhibits NK cells, as blocking
this interaction restores NK activity, whereas introducing
CD48 imposes inhibition.
To further investigate the function of 2B4 on NK cells,
2B4-deficient mice were generated. 2B4 /  mice were
phenotypically normal as were the lymphocyte popula-
tions, including NK cell numbers and the NK receptor
repertoire (unpublished data). We hypothesized that if
CD48 interaction with 2B4 inhibits NK lysis, then 2B4 / 
NK cells will not be inhibited by CD48 expressed on target
cells. To test this hypothesis, IL-2–activated NK cells gen-
erated from 2B4 /  and WT mice were assayed for cyto-
toxicity against RMA-S cells. 2B4 /  and WT NK cells
both lysed CD48  RMA-S cells but as predicted, only
2B4 /  NK cells lysed CD48  targets, and to an extent
equivalent to that of the lysis of CD48  targets (Fig. 1 G).
This confirms that 2B4 ligation on WT NK cells inhibits
NK cytotoxicity because these data are not prone to any
artifacts (such as ADCC or FcR triggering) that are inher-
ent in antibody-blocking experiments.
2B4 Ligation Inhibits NK Cell Lysis of Nontransformed Tar-
gets. NK cells readily lyse allogeneic cells as allogeneic
cells lack the protection of self–MHC class I alleles (34). As
all lymphocytes express CD48 (16), we used Con A–stimu-
lated allogeneic BALB/c splenocytes as targets for B6 NK
effector cells to determine if nontransformed targets also in-
hibit NK cells via 2B4 signaling. As previously reported,
B6 LAK cells lyse H-2d Con A blasts via the Ly49D recep-
tor (35). Such lysis of allogeneic Con A blasts was enhanced
by blocking 2B4–CD48 interaction using anti-CD48–
treated targets or anti-2B4–treated NK cells (Fig. 2 A). This
effect was not T cell mediated, as SCID LAK cells also
showed enhanced killing when CD48 is blocked (Fig. 2 B).
Confirming these results, 2B4 /  NK cells showed en-
hanced killing of allogeneic Con A blasts as compared with
WT NK cells (Fig. 2 C). WT and 2B4 /  NK lysis of
whole B6 splenocytes activated for 2 d did not appear dif-
ferent (Fig. 2 C). A recent report suggested that Con A
blasts made from B cell–depleted spleen cells activated for 1
d are more sensitive to lysis, therefore, 2B4 /  NK cells
were retested according to this protocol (36). Under these
conditions, 2B4 /  NK cells did have increased killing of
B6 splenocytes (Fig. 2 D). These data demonstrate that 2B4
engagement by allogeneic as well as syngeneic, nontrans-
formed cells leads to inhibition of NK cytotoxicity.
In Vitro–derived NK Cells Are Inhibited by 2B4. It has
been proposed that 2B4 is inhibitory on immature human
NK cells until they have matured and acquired MHC class
I inhibitory receptors (24). Ly49  murine NK cells can be
derived by sequential culture of lineage  ckit  multipotent
bone marrow progenitors in early acting cytokines fol-
lowed by IL-2 (30). To determine the role for 2B4 on
these “immature” NK cells, they were assayed for lysis of
CD48  and CD48  RMA-S cells. Ly49  NK cells derived
from bone marrow progenitors lysed CD48  targets, but
were inhibited by the expression of CD48 on the target
cells (Fig. 3 A). Anti-CD48 blocking restored lysis of
Figure 2. Ligation of 2B4 by CD48 expressed on allogeneic and syngeneic
targets inhibits NK cytotoxicity. B6 LAK cells were tested in a cytotoxicity
assay against Con A–stimulated splenic cells at the indicated E/T ratios.
(A) On the left, WT LAK cells were tested against BALB/c targets either
pretreated with anti-CD48 or not treated. On the right, WT LAK cells
pretreated with anti-2B4 or not treated were tested against BALB/c targets.
(B) SCID LAK cells were tested against BALB/c targets either pretreated
with anti-CD48 or untreated. (C) WT and 2B4 /  LAK cells were assayed
against BALB/c or B6 Con A blasts. (D) WT and 2B4 /  LAK cells were
tested against B cell–depleted B6 splenocytes stimulated with Con A for
1 d only.Lee et al. 1249
CD48  targets. 2B4 /  in vitro–derived NK cells were not
inhibited by CD48 expressed on RMA-S targets (Fig. 3
B). Similarly, 2B4 /  in vitro–derived NK cells exhibited
greater killing of allogeneic, as well as syngeneic, Con A
blasts as compared with WT (Fig. 3 C). Thus, as for mature
Ly49  NK cells, in vitro–derived Ly49  NK cells are also
inhibited by 2B4 engagement. The finding that 2B4 is in-
hibitory on developing murine NK cells confirms a previ-
ous report for developing human NK cells (24). However,
in contrast to this previous report, murine 2B4 is inhibitory
even in mature NK cells.
CD48 Expressed on Target Cells Inhibits NK Cell Produc-
tion of IFN- . NK cell IFN-  production and lytic activ-
ity are not always coordinated by the same signaling path-
way, a phenomenon previously ascribed to 2B4 (37, 38).
Therefore, to determine if 2B4 ligation by tumor cells reg-
ulates NK cell inflammatory cytokine production, WT NK
cells were coincubated with RMA-S cells and intracellular
IFN-   accumulation was measured. 24.8% of NK cells
produced IFN-  in response to CD48  RMA-S, whereas
only 8.3% produced IFN-  in response to CD48  RMA-S
(Fig. 4). Blocking CD48–2B4 interaction with anti-CD48
restored NK cell IFN-  production. These data indicate
that like lytic activity, NK IFN-  elaboration is inhibited
by CD48–2B4 interaction.
2B4 Inhibits NK-mediated Clearance of CD48  Tumor Cells
In Vivo. To investigate the role of 2B4 on NK cells not
activated with exogenous IL-2 and in the host environ-
ment, an in vivo peritoneal tumor clearance assay was per-
formed. 2B4 /  and WT mice were injected i.p. with
CFSE-labeled CD48  or CD48  RMA-S cells. After 3 d,
the number of CD48  RMA-S cells in peritoneal lavage
fluid of WT mice was significantly higher than the number
recovered in 2B4 /  mice (Fig. 5). WT mice did reject
CD48  tumor cells, indicating that in the absence of 2B4 li-
gation, WT mice clear tumor cells efficiently. RMA-S cells
are class I low, thus are primarily NK cell targets. However,
we confirmed that clearance in vivo was NK cell mediated,
using NK-depleted WT and 2B4 /  mice. In the absence of
NK cells, 2B4 /  and WT mice had similar accumulation of
tumor cells, demonstrating that 2B4 /  NK cells are re-
quired for tumor clearance. These data demonstrate that
2B4 inhibits NK cell clearance of tumor cells in vivo.
2B4 Long Inhibits Primary NK Cell Cytotoxicity. In mu-
rine NK cells, 2B4 exists as short and long isoforms gener-
ated by alternative splicing that differs only in the cytoplas-
mic tail (7, 8). To determine if exogenous expression of
Figure 3. Ligation of 2B4 on in vitro–derived Ly49  NK cells by
CD48 inhibits cytotoxicity. (A) WT in vitro–derived NK cells were
tested in a 4-h chromium release assay against CD48  and CD48  RMA-S in
the presence of anti-CD48, isotype control, or no antibody at a 50:1 E/T
ratio. (B) WT and 2B4 /  in vitro–derived NK cells were tested against
CD48  or CD48  RMA-S at the indicated E/T ratios. (C) WT and
2B4 /  in vitro–derived NK cells were tested against Con A–stimulated
BALB/c or B6 splenic cells at the indicated E/T ratios.
Figure 4. CD48 on target cells inhibits NK cell IFN-  production.
WT LAK cells pretreated with anti-FcR were incubated at a 1:1 ratio
with CD48  or CD48  RMA-S cells for 6 h. CD48  RMA-S were pre-
treated with anti-CD48 or isotype control. NK cells incubated alone
were used as controls. Cells were gated on the basis of forward and size
scatter to exclude RMA-S and were gated on CD3  NK1.1  cells. Numbers
indicate the percent of NK cells that were IFN-  .2B4 Inhibition of NK Cells 1250
these isoforms could restore inhibition in 2B4-deficient NK
cells, retroviral transduction of primary 2B4 /  NK cells
was performed. Greater than 95% of LAK cells transduced
with short or long expressed 2B4 on the cell surface 24 h af-
ter infection as compared with cells infected with vector
alone (Fig. 6 A). Viability of transduced cells was similar to
control cells as analyzed by forward versus side scatter dis-
crimination of live cells (Fig. 6 B). When the transduced
cells were tested for lysis of CD48  RMA-S cells, control
vector–transduced 2B4 /  cells lysed the targets as expected
(Fig. 6 C). Transduction of 2B4 long restored inhibition of
2B4-deficient NK cells, whereas the short isoform did not.
Comparison of CD48  and CD48  targets revealed that al-
though the vector control– and 2B4 short–transduced cells
had equivalent lysis of CD48  and CD48  target cells, the
lysis of CD48  targets was lower than that of CD48  when
NK cells were transduced with 2B4 long (Fig. 6 D). The
finding that 2B4 long is inhibitory in primary NK cells is in
agreement with a previous report on an NK cell line (39).
However, this data does not confirm the activating role pre-
viously ascribed to 2B4 short.
SH2D1A Expression Does Not Correlate with 2B4-mediated
Inhibition. In the absence of functional SH2D1A, as occurs
in XLP patients, 2B4 is not activating and in some reports is
in fact inhibitory (24, 26–29). Similarly, immature human
NK cells lack SH2D1A and are inhibited by 2B4 ligation
(24), so it could be argued that SH2D1A is necessary for
2B4-activating signals. In agreement with this hypothesis,
we found that in vitro–derived, immature phenotype NK
cells lacked SH2D1A as determined by RT-PCR (Fig. 7
A). However, LAK cells did express SH2D1A transcripts
(Fig. 7 A) and have previously been reported to express
SH2D1A protein (25). The discovery that 2B4 is inhibitory
in both in vitro–derived and mature LAK cells is interesting
in light of the finding that only one of these populations ex-
presses SH2D1A. These findings are at variance with those
reported previously for human NK cells inasmuch as 2B4
acts as an inhibitory receptor regardless of the expression, or
lack thereof, of SH2D1A (24). EAT-2, a protein homolo-
gous to SH2D1A, was expressed at the mRNA level in
both immature and mature NK cells (Fig. 7 B). Thymocytes
were used as a control, as they express SH2D1A but lack
EAT-2 mRNA (18). EAT-2 protein is expressed in NK
cells (40) and binds to murine 2B4 (18), and therefore might
be important for 2B4 inhibitory signaling.
Figure 5. 2B4 engagement inhibits NK rejection of tumor cells in vivo.
WT and 2B4 /  mice were injected i.p. with CFSE-labeled tumor cells.
The number of tumor cells recovered from the peritoneum after 3 d
(depicted on y axis) was calculated on the basis of absolute number of peri-
toneal exudate cells (listed on x axis) multiplied by the percentage that
were tumor cells as determined by flow cytometry. NK-depleted mice
were treated with 100  g anti-NK1.1 on days  2 and 0. Five mice per
group were analyzed per experiment. Data are representative of three inde-
pendent experiments. **, Student’s t test for WT versus 2B4 / ; P   0.0004.
Figure 6. Retroviral transduction of 2B4 long into 2B4 /  NK cells
restores inhibition. 2B4 /  LAK cells were retrovirally transduced with a
vector expressing 2B4 short, 2B4 long, or empty vector control. (A) 24 h
after transduction, cells were analyzed for 2B4 expression (B) and for live
cells by forward and side scatter. Numbers indicate the percent of cells in
the live gate. (C) Transduced cells were tested for killing of CD48 
RMA-S. (D) In a separate experiment, transduced cells were tested for
lysis of CD48  or CD48  RMA-S. Data are representative of at least three
independent experiments.Lee et al. 1251
Discussion
In this study we have investigated the regulation of NK
cells by 2B4 and demonstrated that 2B4 engagement by
CD48 expressed on target cells inhibits NK effector func-
tion. This was demonstrated in multiple ways: reduced lysis
of CD48  targets compared with CD48  targets, reversal of
this inhibition with anti-2B4 and anti-CD48 antibodies,
and loss of inhibition in 2B4-deficient NK cells. The role
of CD48 in delivery of an inhibitory signal to 2B4 on NK
cells was confirmed by transfection of CD48 into two sepa-
rate CD48  tumor cell lines. 2B4-mediated inhibition of
killing was not restricted to CD48  tumor cells and also oc-
curred in response to nontransformed allogeneic and syn-
geneic cells. CD48 expression on target cells also resulted
in decreased inflammatory cytokine production by NK
cells. 2B4 was found to inhibit both immature and mature
NK cells, and these data were further confirmed in vivo by
the increased clearance of tumor cells in 2B4 /  mice.
Previous in vitro data suggested that murine 2B4 acti-
vates NK cells. The results of previous studies are not in-
consistent with our findings. For example, in the original
study looking at 2B4 function, the finding that anti-2B4
Fab fragments also increased lysis of target cells indicated
that cross-linking of 2B4 was not necessary for activation
(10). After the ligand for 2B4 was discovered, it was appre-
ciated that the targets in that experiment were CD48 .
Therefore, the Fab fragments were actually blocking 2B4
engagement with the target, which means blocking inhibi-
tion and thereby permitting NK activation.
Most of the work analyzing murine 2B4 has used anti-
body-mediated cross-linking in vitro, such as redirected
killing and plate-coated antibodies. These approaches may
provide less physiological conditions for studying 2B4
function as opposed to using ligand-expressing targets in
vitro or genetically modified NK cells in vivo. A similar
phenomenon occurred with the receptor CD69. Cross-
linking CD69 with antibody lead to NK cell activation in
vitro, however, subsequent in vivo studies with CD69-
deficient mice indicated that CD69 is a negative regulator
of NK cells (41, 42).
Studies on human 2B4 using CD48  and CD48  cell
lines found that CD48 on target cells activated primary NK
cells in one study, but not in another (13, 43). Discrepan-
cies may stem from other receptors that are coengaged by
the target cell, likely altering the outcome of 2B4 ligation.
This was found to be true in human NK cell clones. Only
those clones that were coengaged by an activating receptor
were regulated by anti-2B4 cross-linking in a redirected ly-
sis assay (44). It is feasible, therefore, that under different
conditions or with different targets, 2B4 signaling can be
negative or positive. The NK receptor CD158d has also
been shown to have both activating and inhibitory capabil-
ities (45). 2B4 may derive this capability from the unique
signaling versatility of ITSM motifs.
We have found that 2B4 ligation inhibits the putative
NK receptor activated by several targets including RMA-S,
T cell blasts, and P815 (Figs. 1 and 2). In the case of P815
and RMA-S, the activating receptor is unknown, but is
likely not NKG2D (46). As P815 and BALB/c targets are
H-2d, then Ly49D might be activating the NK cells in both
cases (35). NK lysis of activated T cells may also be regu-
lated by NKG2D (36). The finding that 2B4 is inhibitory
in the context of these various interactions argues that mu-
rine 2B4 is generally inhibitory when engaged by a target
cell. It has previously been shown that the lysis of H-2d tar-
gets by B6 NK cells in vitro is mediated by Ly49D  NK
cells that lack Ly49C/I/G2 expression (35). It is interesting
to note, therefore, that the Ly49D-mediated lysis of H-2d
Con A blasts (Fig. 2) was augmented by disrupting 2B4–
CD48 interaction. This indicates that the lytic function of
triggering Ly49 receptors can be regulated not only by in-
hibitory Ly49 receptors that bind MHC class I, but also by
non-MHC–recognizing receptors such as 2B4.
Unlike Ly49 and CD94/NKG2 receptors, 2B4 does not
monitor MHC expression. Several observations, particularly
the presence of NK cell self-tolerance in MHC class I–defi-
cient mice and humans, predicted that non-MHC–recog-
nizing inhibitory receptors exist on NK cells (47, 48). This
notion is further supported by the recent discovery of inhib-
itory forms of NKRP1 family members in mice (49). In this
study, NKRP1d, like 2B4, was noted to be expressed on all
splenic NK cells, and it inhibited cytolytic activity by recog-
nition of the Clrb molecule. Unlike CD48 though, Clrb is
expressed mainly on dendritic cells and macrophages.
2B4 and CD48 appear to act in parallel to the “missing
self” system to safeguard against inappropriate NK aggres-
sion against hematopoietic cells. It might be that these two
systems coevolved and are now functionally redundant.
Neither 2B4-deficient mice nor MHC class I–deficient
mice exhibit overt autoimmunity, suggesting this to be the
case. On the other hand, even in the presence of self-MHC
molecules, CD48 is providing additional protection from
NK cells, indicating that MHC and CD48 act nonredun-
dantly (Fig. 2 D). There may also be instances when CD48
alone is protective in the absence of MHC. Developing he-
matopoietic cells may go through MHC class I low stages
where CD48 expression preserves them from NK cells. For
example, CD4  CD8  double positive thymocytes tran-
siently down-regulate MHC class I expression, yet CD48 is
expressed early in thymic development (50, 51). Con-
Figure 7. SH2D1A is differentially expressed in LAK and in vitro–
derived NK cells. Total RNA was isolated from day 5 and day 11 in
vitro–derived NK cells, LAK cells, and thymocytes as a control. RT-PCR
was performed for (A) SH2D1A and (B) EAT-2 mRNA in the presence
and absence of RT. Primers specific for GAPDH were used as a control.2B4 Inhibition of NK Cells 1252
versely, developing NK cells acquire lytic activity before
acquisition of MHC receptors. Early expression of 2B4
may prevent NK cell lysis of neighboring hematopoietic
cells before NK cell acquisition of self-tolerance (24). In-
deed, 2B4 is expressed on developing NK cells before ac-
quisition of Ly49 molecules in vitro (unpublished data). In
agreement with this hypothesis, we found that Ly49  im-
mature NK cells derived from 2B4 /  bone marrow cul-
tures readily lyse syngeneic targets (Fig. 3 C). Likewise, it
has also not been ruled out that 2B4 is necessary for self-
tolerance of a potential population of Ly49  mature NK
cells in the periphery.
The mechanism by which 2B4 inhibits is unknown. It
has been proposed that 2B4 is inhibitory in the absence of
SH2D1A. Yet, we have confirmed that mature NK cells
express SH2D1A transcripts, whereas in vitro–derived NK
cells do not (Fig. 7 A). As both of these cell types are inhib-
ited by 2B4, this finding indicates that the presence or ab-
sence of SH2D1A does not dictate the nature of the 2B4
signal. Corroborating this result is the report that 2B4 in
SH2D1A-deficient mice is not dysfunctional (52), and is ca-
pable of inhibitory signaling (unpublished data). The dis-
crepancy between these data and previous reports might be
due to differences between human and mouse 2B4 interac-
tion with SH2D1A. EAT-2 is a similar protein, the tran-
scripts of which were found in both immature, in vitro–
derived NK cells as well as IL-2–activated NK cells (Fig. 7
B). Although it has been shown to bind 2B4, whether or
not EAT-2 is necessary for 2B4 inhibitory signaling is un-
known (18). 2B4 has also been shown to associate with SH2
domain–containing tyrosine phosphatases, SHP-1 and SHP-2,
thus either of these molecules might be necessary for con-
ducting 2B4 signals (23, 29, 39). We have excluded the re-
quirement for SHP-1, as 2B4 inhibitory signaling is intact in
motheaten viable mice (unpublished data). SH2 domain–
containing inositol-5  phosphatase might be involved, as it
can be recruited to the 2B4 family member, CD150 (53).
In an NK cell line, RNK, exogenous expression of 2B4
long inhibited the NK cells (39). We have found that 2B4
long also inhibits primary NK cells (Fig. 6). As bulk LAK
cultures express both forms (8) but are inhibited by 2B4 li-
gation, this suggests that 2B4 long provides the dominant
signal. 2B4 short was not activating in primary NK cells,
but it has been shown to provide a positive signal in T cells
and RNK cells (31, 39). It is not clear what the biochemi-
cal difference is between the cell types, but the most likely
explanation is the differential expression or recruitment of
local SH2 domain–containing proteins to the ITSM motifs.
NK cells have been shown to interact with and lyse syn-
geneic activated immune cells, including T cells, macro-
phages, and dendritic cells, conceivably to help control or
terminate an immune response (36, 54–56). Intriguingly, the
expression of CD48 is up-regulated on several immune cell
types in response to PMA, IFN- , and IFN- /  (16, 57).
Perhaps ligation of 2B4 by enhanced expression of CD48 is
a means to protect activated immune cells from lysis by NK
cells in the early stages of an immune response. The finding
that 2B4 has an inhibitory effect on NK cells yields a reeval-
uation of how 2B4 and CD48 regulate NK interactions with
target cells as well as other hematopoietic cells.
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